What is Idoven?
Cardiac conditions diagnosed from ECG analysis.
Who is Idoven best for?
Idoven is best for MedTech device makers and pharma teams that need ECG recordings read by certified AI at scale.
MedTech and remote monitoring
Its CE-marked Willem platform reads ECGs from Holters, patches, resting 12-lead machines and implantable monitors, flags arrhythmias for triage and connects to home monitoring and EHR systems.
Pharma and life sciences
It builds ECG-based risk scores to find high-risk or undiagnosed patients and to watch for heart side effects of drugs.
Employers and sports organisations
It runs at-home heart checks with a waterproof ECG device worn for one to seven days, with cardiologists supervising the reading.
Teams with mixed ECG devices
It is device neutral, takes recordings from 30 seconds to 30 days in standard and proprietary formats, and works through an API or other tools.
How much does Idoven cost?
Idoven does not publish prices: its AI cardiology platform is sold to MedTech, life sciences and screening-program customers through a contact form, and the maker states no free plan or trial.
Idoven has no pricing page (idoven.ai/pricing is not found) and shows no plans; each solution page ends in a Contact us form. Plans and current prices are on idoven.ai.
How do readers rate Idoven?
No one has rated Idoven yet. Be the first.
Sign in to rate. One rating per account.
Questions about Idoven
What is Idoven?
Cardiac conditions diagnosed from ECG analysis.
Who is Idoven for?
Idoven is best for MedTech device makers and pharma teams that need ECG recordings read by certified AI at scale.
Is Idoven free?
No. Idoven is a paid tool.
Where can I try Idoven?
On its official website, idoven.ai.
Can Idoven diagnose heart conditions on its own?
No. Idoven says results from Willem, its ECG analysis platform, are advisory for physicians and clinicians and not meant to be the only basis for a diagnosis; it is certified in the EU as a Class IIa medical device for arrhythmia assessment by qualified professionals.







